Across TCGA pan-cancer cohorts, H3P44 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated H3P44 data layer compared with 18 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher H3P44 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated H3P44 expression acts as an unfavorable survival marker.
ESCA are the cancer types where H3P44 Mutation most reproducibly stratifies survival.